News New biotech Avere plots listing via NextCure merger New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.
Sales & Marketing BonelliErede on M&A in Europe: Andrea Carta Mantiglia Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, discusses M&A in Europe.
News Vertex buys Crinetics for $10bn in endocrinology drive Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.
News Novartis snaps up UK ADC developer Myricx Bio Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.
News Ipsen's M&A team strikes again, adding Memo in $700m deal Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.
News Zymeworks cuts deal to buy Theravance for $929m in cash Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.